June 9, 2018 3:05pm

Some say, “There is something lurking out there” – don’t get too comfortable with the sector and market.”

Volume continues low as volatility fluctuates

 

Out and about: Brainstorm Cell Therapy (BCLI) files for $100M mixed shelf offering, shares are down 1.91% or -0.09 to $4.62

 

Of the 45 covered, the 22 downside equities expired in a bottom-weighted range of -$0.01 to -$0.89 with 3 toppers of -$3.50, $1.90 and $1.30 while the 22 upside equities oscillated from +$0.01 to $2.00 with 1 flat close

 

We keep you informed, if you want to be knowledgeable of the “bones” of the sector - be a subscriber to understand what you need to do in Monday’s market. Let the “numbers” speak since sentiment is capricious!

 


Henry’omics:

From the pre-open newsletter … “share pricing is like capturing fog in a glass depending on which way algorithms “rule” or is it just cleaning the cupboards of share pricing risk?”

I also stated, “I am staying out of the session until the waves settle down … although it just may be a day to cherry-pick for next week. Fear is the bottom line for Friday!”

Re the title, “Blackstone’s Byron Wien’s comments came as the Cboe Volatility Index VIX (+0.41%) - one measure of Wall Street fear that tends to fall as stocks rally and surge as they tumble, hit its lowest level since late January.

The so-called VIX, which reflects bullish and bearish options bullish and bearish options bets on the S&P 500 SPX (+ 0.31%), was mostly dormant in 2017. Then it jumped by 116% — the most in its history — back in early February, as the S&P 500 and the Dow Jones Industrial Average DJIA (+0.30%  began a retreat into correction territory. A correction is usually defined as a drop of at least 10% from a recent peak.

Although the Nasdaq (+0.14%) was pulling back as Wien spoke Thursday, the broader market has seen a resurgence in market optimism and decline in volatility underpinned by gains in technology and internet stocks MarketWatch>.

Meanwhile, there will be plenty to knock the stock market and “our” universe around!

Last week, the major averages all rose at least 1.2%.

 

Next week: Don't touch a BUY or SELL ticket until you see the green of their moves!

 

The advance/decline line scenario of 45 covered companies:   

  • The open was negative with an A/DL of 17/23 and 5 flats;
  • 10:30 a.m. continued negative with an A/DL of14/28 and 3 flats
  • The mid-day popped positive with an A/DL of 22/20 and 3 flat3;
  • The close was neutral with an A/DL of 22/22 and 1 flats;

 

June sessions:

  • Friday closed NEUTRAL with 22 decliners, 22 advancers and 1 flat;
  • Thursday closed NEGATIVE with 34 decliners, 9 advancers and 2 flat;
  • Wednesday closed POSITIVE with 17 decliners, 24 advancers and 4 flat;
  • Tuesday closed POSITIVE with 14 decliners, 30 advancers and 1 flat;
  • Monday closed POSITIVE with 18 decliners, 25 advancers and 2 flat;
  • Friday (June 1) closed was POSITIVE with 15 decliners, 29 advancers and 1 flat;

 

MY working five (5) trend lines:

The greatest volume to the downside:  MDXG, VSTM, BMRN, GBT and IONS

Upside volume was weighted to:  ATHX, SGMO, KOOL, CRSP and FATE

Biggest $ downside:  RENE.L (-$3.50), GBT (-$1.90), INOS (-$1.30), SAGE (-$1.29) and RARE (-$0.89)

Best moves to the $ upside: RGNX (+$2.00), EDIT (+$1.40), CRSP (+$1.14), AXGN (+$0.65) and VCEL (+$0.50)

… Flats:  AST

 

Daily analytics:

Stocks rise more than 1% this week, but gains capped by trade tensions

  • The Dow closed 75.12 points or +0.3% higher at 25,316.53.
  • The S&P 500 gained 8.66 points or +0.3% to 2,779.03
  • The NASDAQ closed 10.44 points or 0.14% higher at 7,645.51.

 

The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market,

  • Friday traded at 12.18, up 0.33 %
  • Thursday traded at 12.13, up +4.21%
  • Wednesday traded at 11.64, down -6.13%
  • Tuesday traded at 12.45, down -2.28%
  • Monday traded at 12.74, down -5.35%
  • Last Friday traded at 13.46, down -12.77%

 

The iShares Russell 2000 (IWM) closed:

  • Friday was up +0.30%;
  • Thursday was down -0.55%;
  • Wednesday was up +0.71%;
  • Tuesday was up +0.61%;
  • Monday was up +0.53%;
  • Last Friday was up +0.65%

 

The iShares NASDAQ Biotechnology (IBB) closed:

  • Friday was up +0.32 %
  • Thursday was down -0.69%
  • Wednesday was up +1.25%
  • Tuesday was up +0.03%
  • Monday was down -0.65%
  • Last Friday was up +1.28%

 

The count in June - decliners versus gainers:

……. look at the differences in decliners:

  • Friday’s decliners ranged from -0.19% <CLLS -$0.03 > to -6.35% <BSTG -$0.19> in 22 equities;
  • Thursday’s decliners ranged from -0.08% < BOLD -$0.03> to -23.39% < MDXG -$1.92> in 34 equities;
  • Wednesday’s decliners ranged from -0.02% <SAGE -$0.03> to -4.75% <MESO -$0.28 > in 17 equities;
  • Tuesday’s decliners ranged from -0.13% <BOLD -$0.05> to -4.90% <ADRO -$0.35> in 14 equities;
  • Monday’s decliners ranged from -0.13% <OSIR -$0.01 > to -6.80% <RGNX -$3.65 > in 18 equities;
  • Last Friday’s decliners ranged from -0.09% <IONS -$0.04 > to -26.40% <ONVO -$0.52 > in 15 equities;

Versus

  • Friday’s gainers ranged from +0.16% <QURE +$0.06 > to +10.28% <HSGX +$0.26> in 22 equities;
  • Thursday’s gainers ranged from +0.38% <FIXX +$0.08 > to +9.96% < MESO +$0.56> in 9 equities;
  • Wednesday’s gainers ranged from +0.08% < SLDB +$0.02> to +12.32% <VSTM +0.68 > in 24 equities;
  • Tuesday’s gainers ranged from +0.02% < ALNY +$0.02> to +8.99% <RGNX +$4.50 > in 30 equities;
  • Monday’s gainers ranged from +0.59% <CUR +$0.01 > to +8.90% <BLUE +$8.90 > in 25 equities;
  • Last Friday’s gainers ranged from +0.25% <CLBS +$0.01> to +9.09% <BSTG +$0.25 > in 29 equities;

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.